Keywords
children, Hodgkin lymphoma, relapse
How to Cite
Zubizarreta, P. (2019). Relapsed/refractory pediatric Hodgkin lymphoma. Journal of Hematology, 22(Extraordin), 62–71. Retrieved from https://www.revistahematologia.com.ar/index.php/Revista/article/view/57
Abstract
El linfoma de Hodgkin clásico (LHc) se caracteriza histológicamente por un escaso número de células malignas en un microambiente dominado cuantitativamente por células inmunitarias reactivas. El inmunofenotipo característico de la célula de Hodgkin/Reed Sternberg (HRS) es fuertemente positivo para CD30 e IRF4. El CD15 se observa en sólo el 75% de los casos.
References
1. Jaffe ES, Arber DA, Campo E, Harris NL, Quintanilla-Fend L, eds. Hematopathology. Philadelphia, PA: Elsevier Ltd; 2016.
2. Swerdlow SH, Campo E, Harris N et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
3. Schwab U, Stein H, Gerdes J et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878): 65-67.
4. Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin’s disease. Br J Haematol. 2002;117(2):366-372.
5. Stein H, Uchánska-Ziegler B, Gerdes J, Ziegler A, Wernet P. Hodgkin and Sternberg-Reed cells contain antigens specific to late cells of granulopoiesis. Int J Cancer. 1982; 29(3):283-290.
6. Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin’s and Reed-Sternberg cells. Am J Pathol. 1991;139(4):701-707.
7. Torlakovic E, Tierens A, Dang HD, Delabie J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin’s disease. Am J Pathol. 2001;159(5): 1807-1814.
8. Re D, Müschen M, Ahmadi T et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 2001;61(5): 2080-2084.
9. Steimle-Grauer SA, Tinguely M, Seada L, Fellbaum C, Hansmann M-L. Expression patterns of transcription factors in progressively transformed germinal centers and Hodgkin lymphoma. Virchows Arch. 2003; 442(3):284-293.
10. Krenacs L, Himmelmann AW, Quintanilla-Martinez L et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood. 1998; 92(4):1308-1316.
11. Ushmorov A, Leithäuser F, Sakk O et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood. 2006;107(6): 2493-2500.
12. Dukers DF, van Galen JC, Giroth C et al. Unique polycomb gene expression pattern in Hodgkin’s lymphoma and Hodgkin’s lymphoma-derived cell lines. Am J Pathol. 2004;164(3):873-881.
13. Renné C, Martin-Subero JI, Eickernjäger M et al. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin’s lymphoma. Am J Pathol. 2006; 169(2):655-664.
14. Jundt F, Acikgöz O, Kwon S-H et al. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia. 2008;22(8):1587-1594.
15. Bi G, Jiang G. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol. 2006;3(4):285-290.
16. Younes A, Oki Y, Bociek RG et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011;12(13): 1222-1228.
17. Younes A, Sureda A, Ben-Yehuda D et al. Panobinostat in patients with relapsed/ refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30(18): 2197-2203.
18. Kirschbaum MH, Goldman BH, Zain JM et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma. 2012;53(2):259-262.
19. Du J, Neuenschwander M, Yu Y et al. Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma. Blood. 2017;129(1): 71-81.
20. Polito L, Bortolotti M, Maiello S, Battelli MG, Bolognesi A. Rituximab and other new anti- CD20 Mabs for Non-Hodgkin’s lymphoma treatment. Eur Med J Oncol. 2014;2:63-69.
21. Kochenderfer JN, Dudley ME, Kassim SH et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549.
22. Kantarjian H, Stein A, Gökbuget N et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847.
23. Moskowitz AJ, Schöder H, Yahalom J et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284-292.
24. Chen R, Palmer JM, Martin P et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/ refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136-2140.
25. Moskowitz CH, Nademanee A, Masszi T et al; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2015; 385(9980):1853-1862.
26. Connors JM, Jurczak W, Straus DJ et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331-344.
27. Diepstra A, van Imhoff GW, Karim-Kos HE et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin’s lymphoma. J Clin Oncol. 2007;25(21): 3101-3108.
28. Nijland M, Veenstra RN, Visser L et al. HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune 1662 blood® 12 APRIL 2018 | VOLUME 131, NUMBER 15 MOTTOK and STEIDL checkpoint inhibitor therapy? OncoImmunology. 2017;6(4):e1295202.
29. Reichel J, Chadburn A, Rubinstein PG et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood. 2015;125(7): 1061-1072.
30. Glaser SL, Lin RJ, Stewart SL et al. Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70(4):375-382.
31. Roskrow MA, Suzuki N, Gan Y et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin’s disease. Blood. 1998;91(8):2925-2934.
32. Bollard CM, Aguilar L, Straathof KC et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus1 Hodgkin’s disease. J Exp Med. 2004;200(12):1623-1633.
33. Bollard CM, Gottschalk S, Torrano V et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32(8):798-808.
34. Gerdemann U, Katari U, Christin AS et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011;19(12):2258-2268.
35. Cruz CR, Gerdemann U, Leen AM et al. Improving T-cell therapy for relapsed EBV negative Hodgkin lymphoma by targeting upregulated MAGE-A4(published correction appears in Clin Cancer Res. 2012;18(3):913). Clin Cancer Res. 2011;17(22):7058-7066.
36. Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, Silveira PA, Tsonis C, Cooper WA, Cunningham I, Brown C, Clark GJ, Hart DNJ. CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica. 2018 Apr;103(4):655-665.
37. Joos S, Menz CK, Wrobel G et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99(4): 1381-1387.
38. Barth TFE, Martin-Subero JI, Joos S et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003;101(9):3681-3686.
39. Hartmann S, Martin-Subero JI, Gesk S et al. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma by arraybased comparative genomic hybridization. Haematologica. 2008;93(9):1318-1326.
40. Steidl C, Telenius A, Shah SP et al. Genomewide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood. 2010;116(3):418-427.
41. Joos S, Küpper M, Ohl S et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD301 Hodgkin cells. Cancer Res. 2000;60(3): 549-552.
42. Green MR, Monti S, Rodig SJ et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-3277.
43. Weniger MA, Melzner I, Menz CK et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25(18):2679-2684.
44. Gunawardana J, Chan FC, Telenius A et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet. 2014;46(4): 329-335.
45. Younes A, Romaguera J, Fanale M et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012;30(33):4161-4167.
46. Kim SJ, Kang HJ, Shin D-Y et al. Pilot study of ruxolitinib in relapsed or refractory Hodgkin lymphoma and primary mediastinal large B-cell lymphoma(abstract). Blood. 2014;124(21). Abstract 4443.
47. Szydłowski M, Prochorec-Sobieszek M, Szumera-Ciećkiewicz A et al. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood. 2017;130(12): 1418-1429.
48. Johnston PB, Inwards DJ, Colgan JP et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-324.
49. Oki Y, Buglio D, Fanale M et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013;19(24):6882-6890.
50. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012, 12, 252–264
51. Carey CD, Connelly C, Gjini E, Roemer MG, Stack E, Hodi S, Shipp MA, Rodig SJ. Quantitative assessment of PD-L1 expression in classical Hodgkin lymphoma suggests a critical role for tumor associated macrophages in suppressing anti-tumor immunity. Blood. 2015, 126, 1440.
52. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015 Jun 18;6:e1792.
53. Odorizzi PM, Wherry EJ. Inhibitory receptors on lymphocytes: Insights from infections. J Immunol. 2012, 188, 2957-2965.
54. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006, 439, 682-687.
55. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol. 2015, 15, 45-56.
56. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015, 372, 311-319.
57. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016, 34, 3733-3739.
58. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017, 35, 2125-2132.
59. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J Clin Oncol 2018, 36, 1428-1439.
60. Chen R, Gibb AL, Collins GP, Popat R, El-Sharkawi D, Burton C, Lewis D, Miall FM, Forgie A, Compagnoni A et al. Blockade of the PD-1 checkpoint with anti-PD-L1 antibody avelumab is sufficienct for clinical activity in relapsed/refractory classical Hodgkin lymphoma (CHL). Hematol Oncol. 2017, 35, 67.
61. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018, 131, 1183-1194.
62. Ramchandren R. Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (CHL): Results from the phase 2 checkmate 205 study. In Proceedings of the 59th Annual American Society of Hematology Conference, San Diego, CA, USA, 6 December 2017.
63. Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016, 128, 2489-2496.
64. Green MR, Monti S, Rodig SJ et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-3277.
65. Green MR, Rodig S, Juszczynski P et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611-1618.
66. Metzger ML, Hudson MM, Krasin MJ et al. Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer. 2010;116(18): 4376-84.
67. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97 (3): 616-23.
68. Schellong G, Dörffel W, Claviez A et al. Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol. 2005;23(25): 6181-9.
69. Gorde-Grosjean S, Oberlin O, Leblanc T et al.. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol. 2012;158 (5): 649-56.
70. Nachman JB, Sposto R, Herzog P et al.. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20 (18): 3765-71.
71. Rühl U, Albrecht M, Dieckmann K et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys. 2001;51 (5): 1209-18.
72. Cairo MS, Shen V, Krailo MD et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children’s cancer group report. J Pediatr Hematol Oncol. 2001;23(1): 30-8.
73. Horton TM, Drachtman RA, Chen L et al. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children’s Oncology Group study. Br J Haematol. 2015;170 (1): 118-22.
74. Trippett TM, Schwartz CL, Guillerman RP et al. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children’s oncology group report. Pediatr Blood Cancer. 2015;62 (1): 60-4.
75. Cole PD, Schwartz CL, Drachtman RA et al. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin’s disease: a children’s oncology group report. J Clin Oncol. 2009;27 (9): 1456-61.
76. Shankar A, Hayward J, Kirkwood A et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. Br J Haematol. 2014;165(4): 534-44.
77. Wimmer RS, Chauvenet AR, London WB et al. APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. Pediatr Blood Cancer. 2006;46 (3): 320-4.
78. Sandlund JT, Pui CH, Mahmoud H et al. Efficacy of high-dose methotrexate, ifosfamide etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma. Ann Oncol. 2011;22(2): 468-71.
79. Schulz H, Rehwald U, Morschhauser F et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111 (1): 109-11.
80. Rancea M, Monsef I, von Tresckow B et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;6: CD009411.
81. Aparicio J, Segura A, Garcerá S et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999;10 (5): 593-5.
82. Kobrinsky NL, Sposto R, Shah NR et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease with dexamethasone etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children’s Cancer Group Study CCG-5912. J Clin Oncol. 2001;19 (9): 2390-6.
83. Bonfante V, Viviani S, Santoro A et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin’s disease. Br J Haematol. 1998;103 (2): 533-5.
84. Zinzani PL, Bendandi M, Stefoni V et al. Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease patients. Haematologica. 2000;85 (9): 926-9.
85. Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol. 2000;18 (13): 2615-9.
86. Baker KS, Gordon BG, Gross TG et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. J Clin Oncol. 1999;17 (3): 825-31.
87. Akhtar S, Rauf SM, Elhassan TA et al. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma. Ann Hematol. 2016;95 (9): 1521-35.
88. Shafer JA, Heslop HE, Brenner MK et al. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin’s lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010;51 (4): 664-70.
89. Claviez A, Sureda A, Schmitz N. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;42 (Suppl 2): S16-24.
90. Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- p) and autologous transplantation for patients with Hodgkin’s disease who fail to enter a complete remission after combination chemotherapy. Blood. 1995,86, 451-456.
91. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn JY, Attal M et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: A case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol. 1999, 17, 222-229.
92. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet. 2002, 359, 2065-2071.
93. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006, 12, 1065-1072.
94. Nikolaenko L, Chen R, Herrera AF. Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Ther Adv Hematol. 2017, 8, 293-302.
95. Peniket AJ, Ruiz de Elvira MC, Taghipour G et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31 (8): 667-78.
96. Lieskovsky YE, Donaldson SS, Torres MA et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. J Clin Oncol. 2004;22 (22): 4532-40.
97. Akhtar S, Abdelsalam M, El Weshi A et al. High-dose chemotherapy and autologous stem cell transplantation for Hodgkin’s lymphoma in the kingdom of Saudi Arabia: King Faisal specialist hospital and research center experience. Bone Marrow Transplant. 2008;42 (Suppl 1): S37-S40.
98. Harris RE, Termuhlen AM, Smith LM et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children’s Oncology Group study A5962. Biol Blood Marrow Transplant. 2011;17 (2): 249-58.
99. Wadehra N, Farag S, Bolwell B et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2006;12 (12): 1343-9.
100. Cooney JP, Stiff PJ, Toor AA et al. BEAM allogeneic transplantation for patients with Hodgkin’s disease who relapse after autologous transplantation is safe and effective. Biol Blood Marrow Transplant. 2003;9 (3): 177-82.
101. Claviez A, Klingebiel T, Beyer J et al. Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin’s disease. Ann Hematol. 2004;83 (4): 237-41.
102. Sureda A, Schmitz N. Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin’s disease. Ann Oncol. 2002;13 (Suppl 1): 128-32.
103. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol. 2000;18 (23): 3918-24.
104. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100 (13): 4310-6.
105. Devetten MP, Hari PN, Carreras J et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009;15(1): 109-17.
106. Robinson SP, Sureda A, Canals C et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94 (2): 230-8.
107. Rauf MS, Maghfoor I, Elhassan TA et al. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin’s lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy. Med Oncol. 2015:32 (1): 388.
108. Wadhwa P, Shina DC, Schenkein D et al. Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation? Bone Marrow Transplant. 2002;29 (3): 183-9.
109. Moskowitz CH, Nademanee A, Masszi T et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385 (9980): 1853-62.
110. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S et al. Results of a pivotal phase II study of brentuximab vedotin forpatients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012, 30, 2183-2189.
111. Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016, 128, 1562-1566.
112. O’Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: An international, multicentre, single-arm, phase 1–2 trial. Lancet Oncol. 2018, 19, 257-266.
113. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C et al. Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018 Jul 5;132(1):40-48.
2. Swerdlow SH, Campo E, Harris N et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
3. Schwab U, Stein H, Gerdes J et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878): 65-67.
4. Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin’s disease. Br J Haematol. 2002;117(2):366-372.
5. Stein H, Uchánska-Ziegler B, Gerdes J, Ziegler A, Wernet P. Hodgkin and Sternberg-Reed cells contain antigens specific to late cells of granulopoiesis. Int J Cancer. 1982; 29(3):283-290.
6. Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin’s and Reed-Sternberg cells. Am J Pathol. 1991;139(4):701-707.
7. Torlakovic E, Tierens A, Dang HD, Delabie J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin’s disease. Am J Pathol. 2001;159(5): 1807-1814.
8. Re D, Müschen M, Ahmadi T et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 2001;61(5): 2080-2084.
9. Steimle-Grauer SA, Tinguely M, Seada L, Fellbaum C, Hansmann M-L. Expression patterns of transcription factors in progressively transformed germinal centers and Hodgkin lymphoma. Virchows Arch. 2003; 442(3):284-293.
10. Krenacs L, Himmelmann AW, Quintanilla-Martinez L et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood. 1998; 92(4):1308-1316.
11. Ushmorov A, Leithäuser F, Sakk O et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood. 2006;107(6): 2493-2500.
12. Dukers DF, van Galen JC, Giroth C et al. Unique polycomb gene expression pattern in Hodgkin’s lymphoma and Hodgkin’s lymphoma-derived cell lines. Am J Pathol. 2004;164(3):873-881.
13. Renné C, Martin-Subero JI, Eickernjäger M et al. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin’s lymphoma. Am J Pathol. 2006; 169(2):655-664.
14. Jundt F, Acikgöz O, Kwon S-H et al. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia. 2008;22(8):1587-1594.
15. Bi G, Jiang G. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol. 2006;3(4):285-290.
16. Younes A, Oki Y, Bociek RG et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011;12(13): 1222-1228.
17. Younes A, Sureda A, Ben-Yehuda D et al. Panobinostat in patients with relapsed/ refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30(18): 2197-2203.
18. Kirschbaum MH, Goldman BH, Zain JM et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma. 2012;53(2):259-262.
19. Du J, Neuenschwander M, Yu Y et al. Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma. Blood. 2017;129(1): 71-81.
20. Polito L, Bortolotti M, Maiello S, Battelli MG, Bolognesi A. Rituximab and other new anti- CD20 Mabs for Non-Hodgkin’s lymphoma treatment. Eur Med J Oncol. 2014;2:63-69.
21. Kochenderfer JN, Dudley ME, Kassim SH et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549.
22. Kantarjian H, Stein A, Gökbuget N et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847.
23. Moskowitz AJ, Schöder H, Yahalom J et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284-292.
24. Chen R, Palmer JM, Martin P et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/ refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136-2140.
25. Moskowitz CH, Nademanee A, Masszi T et al; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2015; 385(9980):1853-1862.
26. Connors JM, Jurczak W, Straus DJ et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331-344.
27. Diepstra A, van Imhoff GW, Karim-Kos HE et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin’s lymphoma. J Clin Oncol. 2007;25(21): 3101-3108.
28. Nijland M, Veenstra RN, Visser L et al. HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune 1662 blood® 12 APRIL 2018 | VOLUME 131, NUMBER 15 MOTTOK and STEIDL checkpoint inhibitor therapy? OncoImmunology. 2017;6(4):e1295202.
29. Reichel J, Chadburn A, Rubinstein PG et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood. 2015;125(7): 1061-1072.
30. Glaser SL, Lin RJ, Stewart SL et al. Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70(4):375-382.
31. Roskrow MA, Suzuki N, Gan Y et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin’s disease. Blood. 1998;91(8):2925-2934.
32. Bollard CM, Aguilar L, Straathof KC et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus1 Hodgkin’s disease. J Exp Med. 2004;200(12):1623-1633.
33. Bollard CM, Gottschalk S, Torrano V et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32(8):798-808.
34. Gerdemann U, Katari U, Christin AS et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011;19(12):2258-2268.
35. Cruz CR, Gerdemann U, Leen AM et al. Improving T-cell therapy for relapsed EBV negative Hodgkin lymphoma by targeting upregulated MAGE-A4(published correction appears in Clin Cancer Res. 2012;18(3):913). Clin Cancer Res. 2011;17(22):7058-7066.
36. Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, Silveira PA, Tsonis C, Cooper WA, Cunningham I, Brown C, Clark GJ, Hart DNJ. CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica. 2018 Apr;103(4):655-665.
37. Joos S, Menz CK, Wrobel G et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99(4): 1381-1387.
38. Barth TFE, Martin-Subero JI, Joos S et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003;101(9):3681-3686.
39. Hartmann S, Martin-Subero JI, Gesk S et al. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma by arraybased comparative genomic hybridization. Haematologica. 2008;93(9):1318-1326.
40. Steidl C, Telenius A, Shah SP et al. Genomewide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood. 2010;116(3):418-427.
41. Joos S, Küpper M, Ohl S et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD301 Hodgkin cells. Cancer Res. 2000;60(3): 549-552.
42. Green MR, Monti S, Rodig SJ et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-3277.
43. Weniger MA, Melzner I, Menz CK et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25(18):2679-2684.
44. Gunawardana J, Chan FC, Telenius A et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet. 2014;46(4): 329-335.
45. Younes A, Romaguera J, Fanale M et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012;30(33):4161-4167.
46. Kim SJ, Kang HJ, Shin D-Y et al. Pilot study of ruxolitinib in relapsed or refractory Hodgkin lymphoma and primary mediastinal large B-cell lymphoma(abstract). Blood. 2014;124(21). Abstract 4443.
47. Szydłowski M, Prochorec-Sobieszek M, Szumera-Ciećkiewicz A et al. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood. 2017;130(12): 1418-1429.
48. Johnston PB, Inwards DJ, Colgan JP et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-324.
49. Oki Y, Buglio D, Fanale M et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013;19(24):6882-6890.
50. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012, 12, 252–264
51. Carey CD, Connelly C, Gjini E, Roemer MG, Stack E, Hodi S, Shipp MA, Rodig SJ. Quantitative assessment of PD-L1 expression in classical Hodgkin lymphoma suggests a critical role for tumor associated macrophages in suppressing anti-tumor immunity. Blood. 2015, 126, 1440.
52. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015 Jun 18;6:e1792.
53. Odorizzi PM, Wherry EJ. Inhibitory receptors on lymphocytes: Insights from infections. J Immunol. 2012, 188, 2957-2965.
54. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006, 439, 682-687.
55. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol. 2015, 15, 45-56.
56. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015, 372, 311-319.
57. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016, 34, 3733-3739.
58. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017, 35, 2125-2132.
59. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J Clin Oncol 2018, 36, 1428-1439.
60. Chen R, Gibb AL, Collins GP, Popat R, El-Sharkawi D, Burton C, Lewis D, Miall FM, Forgie A, Compagnoni A et al. Blockade of the PD-1 checkpoint with anti-PD-L1 antibody avelumab is sufficienct for clinical activity in relapsed/refractory classical Hodgkin lymphoma (CHL). Hematol Oncol. 2017, 35, 67.
61. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018, 131, 1183-1194.
62. Ramchandren R. Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (CHL): Results from the phase 2 checkmate 205 study. In Proceedings of the 59th Annual American Society of Hematology Conference, San Diego, CA, USA, 6 December 2017.
63. Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016, 128, 2489-2496.
64. Green MR, Monti S, Rodig SJ et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-3277.
65. Green MR, Rodig S, Juszczynski P et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611-1618.
66. Metzger ML, Hudson MM, Krasin MJ et al. Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer. 2010;116(18): 4376-84.
67. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97 (3): 616-23.
68. Schellong G, Dörffel W, Claviez A et al. Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol. 2005;23(25): 6181-9.
69. Gorde-Grosjean S, Oberlin O, Leblanc T et al.. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol. 2012;158 (5): 649-56.
70. Nachman JB, Sposto R, Herzog P et al.. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20 (18): 3765-71.
71. Rühl U, Albrecht M, Dieckmann K et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys. 2001;51 (5): 1209-18.
72. Cairo MS, Shen V, Krailo MD et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children’s cancer group report. J Pediatr Hematol Oncol. 2001;23(1): 30-8.
73. Horton TM, Drachtman RA, Chen L et al. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children’s Oncology Group study. Br J Haematol. 2015;170 (1): 118-22.
74. Trippett TM, Schwartz CL, Guillerman RP et al. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children’s oncology group report. Pediatr Blood Cancer. 2015;62 (1): 60-4.
75. Cole PD, Schwartz CL, Drachtman RA et al. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin’s disease: a children’s oncology group report. J Clin Oncol. 2009;27 (9): 1456-61.
76. Shankar A, Hayward J, Kirkwood A et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. Br J Haematol. 2014;165(4): 534-44.
77. Wimmer RS, Chauvenet AR, London WB et al. APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. Pediatr Blood Cancer. 2006;46 (3): 320-4.
78. Sandlund JT, Pui CH, Mahmoud H et al. Efficacy of high-dose methotrexate, ifosfamide etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma. Ann Oncol. 2011;22(2): 468-71.
79. Schulz H, Rehwald U, Morschhauser F et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111 (1): 109-11.
80. Rancea M, Monsef I, von Tresckow B et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;6: CD009411.
81. Aparicio J, Segura A, Garcerá S et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999;10 (5): 593-5.
82. Kobrinsky NL, Sposto R, Shah NR et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease with dexamethasone etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children’s Cancer Group Study CCG-5912. J Clin Oncol. 2001;19 (9): 2390-6.
83. Bonfante V, Viviani S, Santoro A et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin’s disease. Br J Haematol. 1998;103 (2): 533-5.
84. Zinzani PL, Bendandi M, Stefoni V et al. Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease patients. Haematologica. 2000;85 (9): 926-9.
85. Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol. 2000;18 (13): 2615-9.
86. Baker KS, Gordon BG, Gross TG et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. J Clin Oncol. 1999;17 (3): 825-31.
87. Akhtar S, Rauf SM, Elhassan TA et al. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma. Ann Hematol. 2016;95 (9): 1521-35.
88. Shafer JA, Heslop HE, Brenner MK et al. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin’s lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010;51 (4): 664-70.
89. Claviez A, Sureda A, Schmitz N. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;42 (Suppl 2): S16-24.
90. Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- p) and autologous transplantation for patients with Hodgkin’s disease who fail to enter a complete remission after combination chemotherapy. Blood. 1995,86, 451-456.
91. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn JY, Attal M et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: A case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol. 1999, 17, 222-229.
92. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet. 2002, 359, 2065-2071.
93. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006, 12, 1065-1072.
94. Nikolaenko L, Chen R, Herrera AF. Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Ther Adv Hematol. 2017, 8, 293-302.
95. Peniket AJ, Ruiz de Elvira MC, Taghipour G et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31 (8): 667-78.
96. Lieskovsky YE, Donaldson SS, Torres MA et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. J Clin Oncol. 2004;22 (22): 4532-40.
97. Akhtar S, Abdelsalam M, El Weshi A et al. High-dose chemotherapy and autologous stem cell transplantation for Hodgkin’s lymphoma in the kingdom of Saudi Arabia: King Faisal specialist hospital and research center experience. Bone Marrow Transplant. 2008;42 (Suppl 1): S37-S40.
98. Harris RE, Termuhlen AM, Smith LM et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children’s Oncology Group study A5962. Biol Blood Marrow Transplant. 2011;17 (2): 249-58.
99. Wadehra N, Farag S, Bolwell B et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2006;12 (12): 1343-9.
100. Cooney JP, Stiff PJ, Toor AA et al. BEAM allogeneic transplantation for patients with Hodgkin’s disease who relapse after autologous transplantation is safe and effective. Biol Blood Marrow Transplant. 2003;9 (3): 177-82.
101. Claviez A, Klingebiel T, Beyer J et al. Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin’s disease. Ann Hematol. 2004;83 (4): 237-41.
102. Sureda A, Schmitz N. Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin’s disease. Ann Oncol. 2002;13 (Suppl 1): 128-32.
103. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol. 2000;18 (23): 3918-24.
104. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100 (13): 4310-6.
105. Devetten MP, Hari PN, Carreras J et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009;15(1): 109-17.
106. Robinson SP, Sureda A, Canals C et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94 (2): 230-8.
107. Rauf MS, Maghfoor I, Elhassan TA et al. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin’s lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy. Med Oncol. 2015:32 (1): 388.
108. Wadhwa P, Shina DC, Schenkein D et al. Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation? Bone Marrow Transplant. 2002;29 (3): 183-9.
109. Moskowitz CH, Nademanee A, Masszi T et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385 (9980): 1853-62.
110. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S et al. Results of a pivotal phase II study of brentuximab vedotin forpatients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012, 30, 2183-2189.
111. Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016, 128, 1562-1566.
112. O’Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: An international, multicentre, single-arm, phase 1–2 trial. Lancet Oncol. 2018, 19, 257-266.
113. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C et al. Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018 Jul 5;132(1):40-48.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar
Downloads
Download data is not yet available.